Drugs: — Aromatic or modified aromatic: — Other
N334168 · 2023-08-15 — The tariff classification of Ensifentrine (CAS No. 1884461-72-6) in bulk powder form, from Portugal
, you requested a tariff classification ruling. Ensifentrine is a novel, selective, dual phosphodiesterase (PDE)3 and PDE4 inhibitor with bronchodilator and anti-inflammatory effects. It is an investigational drug indicated for the treatment of Chronic Obstructive Pulmonary Disorder (COPD). In a follow-up email to this office, you stated Ensifentrine has completed phase 3 clinical trials and submitted a new drug application to the FDA in June of this year. The applicable subheading for the Ensifentrine in bulk powder form will be 2933.59.5300, Harmonized Tariff Schedule of the United States…
N329297 · 2022-12-07 — The tariff classification of Ruxolitinib Phosphate (CAS No. 1092939-17-7) in bulk powder form, from Taiwan
Ruxolitinib Phosphate is the phosphate salt form of Ruxolitinib, an orally bioavailable Janus-associated kinase (JAK) inhibitor. It is indicated for the treatment of patients with intermediate or high-risk myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. The applicable subheading for the Ruxolitinib Phosphate in bulk powder form will be 2933.59.5300, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Heterocyclic compounds with nitrogen hetero-atom(s) only: Compounds containing a pyrimidine ring (whether or not…
N329037 · 2022-11-21 — The tariff classification of Trilaciclib Dihydrochloride (CAS No. 1977495-97-8) and Ruxolitinib Phosphate (CAS No. 1092939-17-7) in bulk form, from Taiwan
, Ltd. Trilaciclib Dihydrochloride is a kinase inhibitor indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer. Ruxolitinib Phosphate is the phosphate salt form of ruxolitinib, an orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. It is indicated for the treatment of intermediate or high-risk myelofibrosis (MF), polycythemia vera (PV) and…
N320984 · 2021-09-07 — The tariff classification of Vibegron (CAS No. 1190389-15-1) in bulk form, from India
Vibegron is a beta-3 adrenergic receptor (ß3) agonist used in the treatment of patients with overactive bladder (OAB) with symptoms of urge urinary incontinence (UUI), urgency, and urinary frequency. The applicable subheading for the Vibegron in bulk form will be 2933.59.5300, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Heterocyclic compounds with nitrogen hetero-atom(s) only: Compounds containing a pyrimidine ring (…) or piperazine ring in the structure: Other: Drugs: Aromatic or modified aromatic: Other.” The rate of duty will be 6.5 percent ad valorem.…
N318947 · 2021-05-14 — The tariff classification of Vericiguat (CAS No. 1350653-20-1) in bulk form and Verquvo® Tablets in dosage form, from Germany
Vericiguat is a soluble guanylate cyclase stimulator indicated to reduce the risk of cardiovascular death and heart failure. Verquvo, imported in 2.5 mg, 5 mg and 10 mg tablets, contains Vericiguat as the active ingredient. It is indicated to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous (IV) diuretics in adults with symptomatic chronic heart failure and ejection fraction less than 45%. The applicable subheading for the Vericiguat in bulk form will be 2933.59.5300, Harmonized Tariff…
Not sure this code fits your product? HaiLang AI determines the US HTS code from a description in about a minute.
Classify a product